On August 22, 2024, Sutro Biopharma, Inc. (NASDAQ: STRO), a South San Francisco-based clinical-stage oncology company, announced critical developments in its oncology portfolio centering around its pioneering site-specific and novel-format antibody drug conjugates (ADCs). The company s latest press release highlights significant progress in two key clinical trials, namely the REFRME-O1 trial for platinum-resistant ovarian cancer (PROC) and the launch of the REFRME-L1 Phase 2 trial targeting non-small cell lung cancer (NSCLC).
REFRME-O1 Trial Outcomes for Platinum-Resistant Ovarian Cancer
In a notable announcement, Sutro Biopharma reported that it has selected a starting dose of 5.2 mg/kg for luveltamab tazevibulin (luvelta) in the randomized portion (Part 2) of the ongoing registrational REFRME-O1 trial focused on patients with PROC. The selection of this specific dose was largely underscored by promising results from the dose-optimization portion of the trial, which showed a remarkable 32% response rate (ORR) among evaluable patients.
This response rate provides pivotal initial evidence supporting the efficacy of luvelta as a treatment option for patients whose ovarian cancer has proven resistant to platinum-based therapies, a condition that has historically posed significant treatment challenges. The results from this trial segment are anticipated to bolster the ongoing clinical narrative around luvelta’s potential as a therapeutic option in this difficult-to-treat patient population.
As Part 2 of the REFRME-O1 trial is now open for enrollment, it represents a crucial step not only towards addressing unmet medical needs in PROC but also towards establishing the clinical profile and potential regulatory pathway for luvelta as a viable treatment alternative.
Launching the REFRME-L1 Phase 2 Trial for Non-Small Cell Lung Cancer
In a concurrent effort, Sutro Biopharma has initiated the REFRME-L1 Phase 2 trial of luvelta, focusing on patients with non-small cell lung cancer (NSCLC) whose tumors express Folate Receptor- (FR). This global study is now open for enrollment, and preliminary data is targeted for release in the first half of 2025.
The REFRME-L1 trial aims to explore the efficacy and safety of luvelta in a specific subset of lung cancer patients, which adds another layer of significance to the ongoing exploration of this innovative therapeutic agent. Given that NSCLC represents one of the most prevalent forms of lung cancer, the initiation of REFRME-L1 may provide deeper insights into the role of luvelta in treating cancers characterized by FR expression.
Conclusion
Both the progress in the REFRME-O1 trial and the initiation of the REFRME-L1 Phase 2 trial reflect Sutro Biopharma’s commitment to advancing cancer care through innovative ADCs. The selected dose of luvelta, along with the successful engagement of patients in these critical studies, sets the stage for potentially transformative changes in how these hard-to-treat cancers are managed.
As developments continue to unfold in the realm of oncology, Sutro Biopharma’s work stands out as a beacon of hope for patients battling both platinum-resistant ovarian cancer and non-small cell lung cancer.
Comments